All relevant data are within the paper and its Supporting Information files.

Introduction {#sec009}
============

Selective serotonin reuptake inhibitors (SSRIs) are among the most widely prescribed psychiatric medications in many countries \[[@pmed.1001875.ref001]--[@pmed.1001875.ref006]\]. At the same time, concerns about their adverse effects, including suicide and violence, have been widely discussed and remain controversial. Observational and trial data have shown that although SSRIs appear not to elevate the risk for suicidal behaviour in adults, they may increase the risk of suicide ideation in children, adolescents, and young adults. This weak age-related association is consistent across studies \[[@pmed.1001875.ref007]--[@pmed.1001875.ref011]\] but inconsistently supported by ecological data \[[@pmed.1001875.ref012]--[@pmed.1001875.ref015]\].

Despite a number of legal cases linking SSRIs and violent behaviour \[[@pmed.1001875.ref016]\], empirical research on the association is limited and inconclusive. Ecological studies suggest that increased SSRI prescriptions have been associated with decreases in violent crimes in the US \[[@pmed.1001875.ref017]\] and lethal violence in the Netherlands \[[@pmed.1001875.ref018]\]. In contrast, an expert review of clinical trials concluded that there was an excess of violence in both adults and children on SSRIs compared with placebo \[[@pmed.1001875.ref016]\]. Furthermore, drug safety (or pharmacovigilance) data have shown a disproportionate association between SSRIs and violent behaviours \[[@pmed.1001875.ref019]\] and serious violent acts \[[@pmed.1001875.ref020]\], and an observational study found an association of work-related violence with antidepressant purchases \[[@pmed.1001875.ref021]\]. However, these study designs are limited: findings from ecological data fail to relate the use of SSRIs at the individual level and are liable to be influenced by secular changes, including legislation, reporting of violence, and unaccounted changes in the impact of other risk factors such as drug and alcohol use \[[@pmed.1001875.ref015],[@pmed.1001875.ref022]\]. Pharmacovigilance data are subject to reporting bias, changes in patient awareness about adverse outcomes, confounding by indication, and failure to account for exposure to other medications \[[@pmed.1001875.ref023]\].

Pharmacoepidemiological studies provide one approach to deal with these limitations \[[@pmed.1001875.ref012],[@pmed.1001875.ref023]\]. Our objective was thus to investigate the association between SSRIs and violence outcomes by linking data from Swedish national registers on individual SSRI prescriptions, use of other psychotropic drugs, and violent crimes in a large population-based cohort. We have primarily used a "within-individual" design \[[@pmed.1001875.ref024]--[@pmed.1001875.ref027]\], where the risk of violent crime is determined when an individual is taking an SSRI as compared to when the same person is not. Using this design, all time-invariant factors (i.e., genetic factors, all factors before the start of follow-up, and factors that remain constant during follow-up) are accounted for; thus, this design more fully adjusts for unmeasured time-invariant confounding and confounding by indication than other observational designs, but does not account for time-varying factors such as symptom severity. Our null hypothesis was that no associations between SSRI medication and violent outcomes would be demonstrated using a within-individual design, including in different age groups.

Methods {#sec010}
=======

In the total population of Sweden aged 15 y or older in 2006 (*n* = 7,917,854) and residing in Sweden during follow-up (January 1, 2006, to December 31, 2009), we identified 856,493 individuals who were prescribed SSRI treatment. Information on individuals receiving SSRI treatment was collected from Swedish population-based registers with national coverage, and registers were linked using each individual's unique identification number. The project was approved by the ethics committee at Karolinska Institutet (2005/4:5).

Measures {#sec011}
--------

### SSRI treatment {#sec012}

Information on medication and the date prescriptions were dispensed was extracted from the Swedish Prescribed Drug Register, with complete national data on all prescribed and dispensed medical drugs from all pharmacies in Sweden since July 2005 \[[@pmed.1001875.ref028]\]. A previous comparison between post-mortem toxicology and SSRI purchases in the Swedish Prescribed Drug Register indicated good medication compliance \[[@pmed.1001875.ref029]\].

In our initial analysis, we included all individuals with dispensed SSRI prescriptions. However, as prescriptions are typically restricted to at most 3 mo and we wanted to restrict the sample to those adherent to SSRIs, individuals with a single SSRI prescription within a 6-mo period were excluded from stratified and sensitivity analyses as no assumptions could be made about their medication adherence. A separate analysis was also carried out including only individuals with a single dispensed prescription. A treatment period was thus defined as a series of SSRI prescriptions with no more than 6 mo between two consecutive prescriptions. The start of a treatment period was defined as the date an SSRI prescription was first dispensed during our follow-up. The end of a treatment period was defined as the date that the last SSRI prescription in that treatment period was dispensed. Periods of more than 6 mo between prescriptions were considered non-treatment periods. A new treatment period was considered to have started at the first date of the next series of consecutive prescriptions (see [S1 Methods](#pmed.1001875.s002){ref-type="supplementary-material"} for details on SSRI medications). For individuals with a single prescription, the start of their treatment period was defined as the date their prescription was dispensed, and the end of that treatment period was defined as 14 d after the prescription was dispensed.

### Other psychotropic medications {#sec013}

Adjustments were made for concurrent psychotropic medications other than SSRIs, which included antipsychotics, hypnotics, sedatives, anxiolytics, drugs used in addictive disorders, mood stabilisers, antiepileptics, and antidepressant medications other than SSRIs (venlafaxine, duloxetine, tricyclics, heterocyclics, mirtazapine, non-selective monoamine oxidase inhibitors, moclobemide, and bupropion). Treatment periods were defined in the same manner as SSRI treatment periods (see [S1 Methods](#pmed.1001875.s002){ref-type="supplementary-material"} for details).

### Violent crimes {#sec014}

Information on convictions for violent crimes for individuals aged 15 y and older (the age of criminal responsibility) was extracted from the Swedish national crime register. Violent crimes were defined as crimes against persons as per previous work \[[@pmed.1001875.ref030]\], and included attempted, completed, and aggravated forms of homicide, manslaughter, unlawful threats, harassment, robbery, arson, assault, assault on an official, kidnapping, stalking, coercion, and all sexual offences (see [S1 Methods](#pmed.1001875.s002){ref-type="supplementary-material"} for more details).

### Alternative outcomes {#sec015}

Examinations of individual SSRIs and alternative outcomes were also carried out, including (1) convictions for substance-related crimes, (2) convictions for non-violent crimes, (3) arrests with preliminary investigations (hereafter "arrests", as distinct from convictions; described as "suspicions" in the Swedish crime register) for violent crimes, (4) arrests for substance-related crimes, (5) arrests for non-violent crimes, (6) non-fatal injuries (hospitalisations) from accidents; (7) emergency inpatient or outpatient treatment for alcohol intoxication or misuse, (8) and psychiatric hospitalisations (see [S1 Methods](#pmed.1001875.s002){ref-type="supplementary-material"} for details on alternative outcomes).

Statistical Analyses {#sec016}
--------------------

Individuals were followed from January 1, 2006, to December 31, 2009, and follow-up was adjusted for migration, periods in prison or institutional youth care, hospitalisation, and death through linkage to the Swedish migration, prison, patient, and cause of death registers. Unobservable time, i.e., time abroad, in prison, or in hospital, was removed (truncated) from the follow-up time. Time after hospital discharge, release from prison, or immigration was added to the observable cohort again.

A between-individual Cox proportional hazards regression compared the average rate of violent crime convictions during SSRI medication with the rate during non-medication for all individuals. In this analysis, follow-up period was split into the period before the first outcome, periods between outcomes, and the period after the last outcome. Time at risk was measured from the start of each period, and medication was used as a time-varying covariate. Robust standard errors were calculated to account for correlations between periods within the same individual. This analysis was adjusted for sex and age.

The principal analyses were within-individual stratified Cox proportional hazards regressions, with each individual entering as a separate stratum in the analysis and serving as his/her own control. The obtained hazard ratio (HR) is thus adjusted for (i.e., stratified by) all potential time-invariant confounders within each individual. To adjust for age, which is a time-varying potential confounder, age was added to the model as a time-varying covariate, with one factor for each whole year. In the within-individual stratified Cox proportional hazards regression, only individuals who changed medication status contributed directly to the estimate. All other individuals contributed indirectly through the estimates of other covariates. Since the covariates in the within-individual stratified Cox proportional hazards regression were time-varying, we did not test for the proportional hazards assumption. More information on this approach is provided in \[[@pmed.1001875.ref031]\]; this approach has been applied in studies of attention deficit hyperactivity disorder medication, antipsychotics, and mood stabilisers \[[@pmed.1001875.ref024]--[@pmed.1001875.ref027]\]. To ensure that outcomes were measured appropriately, all crimes were included from the date of perpetration (rather than conviction), and those with uncertain date of perpetration were excluded from the analyses, resulting in the exclusion of 1.3% (1,241) of violent crime convictions, 1.0% (9,108) of non-violent crime convictions, and 1.8% (5,187) of substance-related convictions during the period from 2006 to 2009.

To test for confounding by other psychotropic medications, we first adjusted for concurrent exposure to other psychotropic medications as a time-varying covariate. Then we excluded individuals with other psychotropic medications during follow-up from the within-individual stratified Cox proportional hazards regression. Analyses were also stratified by sex, by age (from age 15 y, the age of criminal responsibility, in 10-y bands \[[@pmed.1001875.ref032]\] up to age 44 y; the age bands for ages 45 y and over were combined as event rates were low), and by type of SSRI medication (fluoxetine, citalopram, paroxetine, sertraline, or escitalopram).

To estimate cumulative exposure to SSRIs, the defined daily dose (DDD) of SSRI medication \[[@pmed.1001875.ref033]\] was calculated through summing dispensed medication and then dividing the sum by the number of days in the treatment period. DDDs were categorised into four groups; (1) no exposure, (2) low SSRI exposure (\<1 DDD/day), (3) moderate SSRI exposure (1--2 DDD/day), and (4) high SSRI exposure (\>2 DDD/day).

### Sensitivity analyses {#sec017}

In sensitivity analyses, within-individual stratified Cox proportional hazards regressions were carried out with the following alternative outcomes: convictions for non-violent crimes, convictions for substance-related crimes, arrests for violent crimes, arrests for non-violent crimes, arrests for substance-related crimes, non-fatal injuries from accidents, emergency treatment for alcohol intoxication or misuse, and psychiatric hospitalisations. Furthermore, each SSRI medication was analysed separately, and periods of using of two or more SSRI medications were excluded to adjust for switching effects between SSRI medications. Furthermore, all SSRIs were entered in the same model as covariates to adjust for concurrent use of other SSRIs. Analyses were also stratified by type of SSRI medication with violent crime arrests as an alternative outcome. Additionally, other antidepressants (venlafaxine, duloxetine, tricyclics, heterocyclics, mirtazapine, moclobemide, and bupropion) were used as an alternative exposure for violent crime convictions. Further sensitivity analyses were carried out to test for non-specific treatment effects where diuretics were used as an alternative exposure for violent crime convictions to test the model.

For individuals who started SSRI treatment after being convicted of a violent crime, the number of days between the date of committing the crime and the start of SSRI treatment was calculated. To exclude the possibility of reverse causation, i.e., if committing a violent crime increased the probability of subsequent SSRI treatment, new within-individual stratified Cox proportional hazards regressions were carried out excluding from the analysis all individuals who received SSRI treatment within 7, 14, 30, or 60 d after committing a violent crime.

Finally, the robustness of results was tested by undertaking four alternative analyses. First, a conditional Poisson regression examined how changes in medication exposure were associated with changes in violent crime convictions within the same person, thus adjusting for time-invariant confounders. Second, we repeated the main models with different definitions of a treatment period: (1) a series of SSRI prescriptions with no more than 3 mo between two consecutive prescriptions and (2) a series of SSRI prescriptions with no more than 4 mo between two consecutive prescriptions. Third, we tested for delayed onset of action of SSRIs by setting the first day of the treatment period to 8 wk after the date of the first dispensed prescription. Fourth, we tested for SSRI discontinuation effects by extending the end of the treatment period to 3 wk and 12 wk after the date that the last SSRI prescription in a treatment period was dispensed.

SAS version 9.4 (SAS Institute) was used for all analyses, except for the conditional Poisson regression, for which STATA 13.1 (StataCorp) was used. For SAS, software function "proc phreg" was used for both stratified and marginal Cox regressions, and for STATA, software function "xtpoisson" was used for the conditional Poisson regression. STROBE guidelines were followed ([S1 STROBE](#pmed.1001875.s001){ref-type="supplementary-material"}).

Results {#sec018}
=======

Sample Description {#sec019}
------------------

Of 7,917,854 individuals in the general population investigated (individuals in Sweden aged 15 y or older in 2006), 856,493 (10.8%) were prescribed SSRIs during the time period 2006--2009, or 14.1% of all women and 7.5% of all men in the investigated population (see [Table 1](#pmed.1001875.t001){ref-type="table"} for background characteristics). Of those prescribed SSRIs, 9.9% were aged 15--24 y, 12.7% were aged 25--34 y, 16.5% were aged 35--44 y, 15.6% were aged 45--54 y, 15.5% were aged 55--64 y, and 29.7% were aged 65 y or over at baseline in 2006. In the SSRI cohort, 8,377 individuals (1.0%) were convicted of a violent crime during the period 2006--2009. Among the individuals who were prescribed SSRI treatment, 65,862 individuals were prescribed fluoxetine, 389,857 citalopram, 46,615 paroxetine, 215,873 sertraline, 1,198 fluvoxamine, and 84,934 escitalopram.

10.1371/journal.pmed.1001875.t001

###### Characteristics at baseline and during follow-up for SSRI-medicated and non-medicated individuals in a population sample in Sweden 2006--2009.

![](pmed.1001875.t001){#pmed.1001875.t001g}

  Characteristic                                                       Non-Medicated       SSRI-Medicated[^ǂ^](#t001fn002){ref-type="table-fn"}
  -------------------------------------------------------------------- ------------------- ------------------------------------------------------
  ***Characteristics at baseline***                                                        
  **Sex**                                                                                  
  Women                                                                48.8% (3,443,970)   65.9% (564,278)
  Men                                                                  51.2% (3,617,391)   34.1% (292,215)
  **Age**                                                                                  
  15 to 24 y                                                           20.4% (1,439,183)   9.9% (84,647)
  25 to 34 y                                                           14.7% (1,039,843)   12.7% (108,928)
  35 to 44 y                                                           16.2% (1,144,303)   16.5% (141,375)
  45 to 54 y                                                           14.6% (1,029,305)   15.6% (133,996)
  55 to 64 y                                                           15.3% (1,082,914)   15.5% (132,995)
  65 y and over                                                        18.8% (1,325,813)   29.7% (254,552)
  **Lifetime psychiatric diagnoses**                                                       
  Psychotic disorder                                                   0.9% (63,242)       3.3% (27,838)
  Mood disorder                                                        2.0% (143,910)      23.2% (198,366)
  Anxiety, dissociative, stress-related, or somatoform disorder        2.6% (180,735)      20.3% (173,665)
  Eating disorder                                                      0.2% (10,965)       1.2% (10,414)
  Substance (alcohol and drug) use disorder                            2.7% (193,164)      9.1% (77,746)
  ***Characteristics during follow-up***                                                   
  **Other psychotropic medications**                                                       
  Antipsychotic                                                        0.3% (24,515)       0.9% (7,998)
  Hypnotic, sedative, or anxiolytic                                    11.5% (814,717)     37.4% (319,987)
  Drug used in addictive disorders                                     1.1% (74,736)       2.5% (21,494)
  Mood stabiliser                                                      0.8% (58,519)       2.5% (21,151)
  Antiepileptic medication                                             1.0% (74,474)       3.4% (28,722)
  Venlafaxine                                                          0.5% (32,911)       3.0% (25,906)
  Duloxetine                                                           0.3% (18,135)       2.2% (18,871)
  Tricyclic                                                            1.7% (116,963)      4.7% (40,272)
  Heterocyclic                                                         0.2% (11,622)       2.3% (19,770)
  Mirtazapine                                                          1.4% (95,223)       14.0% (119,757)
  Non-selective monoamine oxidase inhibitor                            \<0.1% (133)        \<0.1% (86)
  Moclobemide                                                          \<0.1% (1,669)      0.2% (1,548)
  Bupropion                                                            0.5% (37,116)       2.1% (17,952)
  Any psychotropic medicine other than SSRIs                           19.3% (1,360,733)   75.1% (643,514)
  **Outcomes**                                                                             
  Convicted of a violent crime                                         0.6% (40,384)       1.0% (8,377)
  Convicted of a non-violent crime                                     2.5% (178,622)      3.3% (28,358)
  Convicted of a substance-related crime                               1.0% (67,044)       1.7% (14,625)
  Arrested for a violent crime                                         1.9% (135,495)      3.0% (25,624)
  Arrested for a non-violent crime                                     3.8% (270,203)      5.6% (47,244)
  Arrested for a substance-related crime                               1.2% (82,723)       2.1% (17,787)
  Non-fatal injury from an accident                                    14.0% (991,329)     21.0% (179,734)
  Emergency treatment for alcohol intoxication or misuse               0.9% (66,659)       2.8% (24,141)
  Psychiatric hospitalisation                                          1.2% (86,912)       9.5% (81,406)
  **Periods of SSRI exposure** [\*](#t001fn003){ref-type="table-fn"}                       
  No SSRI exposure                                                                         49.4% (10,540,144)
  Low SSRI exposure (\<1 DDD/day)                                                          16.2% (3,466,382)
  Moderate SSRI exposure (1--2 DDD/day)                                                    24.9% (5,327,339)
  High SSRI exposure (\>2 DDD/day)                                                         9.5% (2,026,178)

Data are given as percent (*n*). See [S1 Methods](#pmed.1001875.s002){ref-type="supplementary-material"} for details on characteristics at baseline and during follow-up.

^**ǂ**^Including all individuals with dispensed SSRI prescriptions.

\*Numbers are periods of SSRI exposure rather than individuals.

Main Analyses {#sec020}
-------------

Within-individual Cox proportional hazards analyses were carried out to compare violent crime rates within the same individuals during periods when they were on medication compared to periods when they were not, and the results showed an increased risk of violent crime conviction during medicated periods (HR = 1.19, 95% CI 1.08--1.32, *p* \< 0.001; [Table 2](#pmed.1001875.t002){ref-type="table"}). The estimated hazard did not materially change when we adjusted for concurrent psychotropic medications (HR = 1.22, 95% CI 1.11--1.32, *p \<* 0.001), nor when we excluded individuals with only one dispensed prescription (HR = 1.22, 95% CI 1.10--1.35, *p \<* 0.001). Additionally, when we excluded all individuals who had received other psychotropic medications during follow-up from the analysis, the estimated hazard was similar (HR = 1.20, 95% CI 1.04--1.38, *p =* 0.014). The between-individual Cox proportional hazards analysis also demonstrated an association between SSRI prescriptions and being convicted of a violent crime (HR = 2.66, 95% CI 2.54--2.78, *p \<* 0.001) when comparing individuals on SSRIs to individuals who were not taking SSRIs.

10.1371/journal.pmed.1001875.t002

###### Violent crime convictions in 2006--2009 in individuals treated with SSRI medication as compared to non-medicated individuals, and comparing treatment to non-treatment periods within the same person.

![](pmed.1001875.t002){#pmed.1001875.t002g}

  Analysis                                                                     HR (95% CI)         *p*-Value   Number of Events
  ---------------------------------------------------------------------------- ------------------- ----------- ------------------
  **Within-individual stratified Cox proportional hazards regression**                                         
  All individuals[^ǂ^](#t002fn001){ref-type="table-fn"}                        1.19 (1.08--1.32)   \<0.001     11,225
  Excluding individuals with only one dispensed prescription                   1.22 (1.10--1.35)   \<0.001     8,592
  Including only individuals with only one dispensed prescription              0.73 (0.45--1.17)   0.193       3,949
  **Analysis adjusted for concurrent psychotropic medication**                                                 
  All individuals adjusted for other psychotropic medications                  1.22 (1.11--1.32)   \<0.001     11,225
  Excluding individuals with other psychotropic medications during follow-up   1.20 (1.04--1.38)   0.014       5,949
  **Between-individual Cox proportional hazards regression**                                                   
  All individuals[^ǂ^](#t002fn001){ref-type="table-fn"}                        2.66 (2.54--2.78)   \<0.001     62,342

^**ǂ**^Including all individuals with dispensed SSRI prescriptions.

The analyses were then stratified by sex and age band ([Table 3](#pmed.1001875.t003){ref-type="table"}). This demonstrated an increased risk of violent crime conviction for those aged 15 to 24 y (HR = 1.43, 95% CI 1.19--1.73, *p \<* 0.001) but not for the other age bands investigated (25--34 y, 35--44 y, and 45 y and older). When stratified by sex and age, associations were significant for both genders in the age group 15 to 24 y (HR = 1.40, 95% CI 1.13--1.73, *p =* 0.002, and HR = 1.75, 95% CI 1.08--2.84, *p =* 0.023, for males and females respectively). Next, the role of cumulative SSRI exposure was examined using DDDs. The results showed that low SSRI exposure was associated with an increased risk of being convicted of a violent crime as compared to periods of non-exposure (HR = 1.27, 95% CI 1.10--1.47, *p =* 0.001). However, no significant association with violent crime conviction was found for periods of moderate or high SSRI exposure ([Table 3](#pmed.1001875.t003){ref-type="table"}).

10.1371/journal.pmed.1001875.t003

###### Violent crime convictions in 2006--2009 in individuals treated with SSRI medication compared to non-treatment periods in the same person stratified by sex, age, dose, and medication type using stratified Cox regression models.

![](pmed.1001875.t003){#pmed.1001875.t003g}

  Characteristic                 HR (95% CI)         *p*-Value   Number of Events   Absolute Risk, Percent (*n*)
  ------------------------------ ------------------- ----------- ------------------ ------------------------------
  **Sex**                                                                           
  Males                          1.22 (1.09--1.37)   \<0.001     6,905              2.1 (5,020)
  Females                        1.21 (0.94--1.56)   0.141       1,687              0.3 (1,418)
  **Age**                                                                           
  15 to 24 y                     1.43 (1.19--1.73)   \<0.001     2,798              3.0 (2,081)
  25 to 34 y                     1.20 (0.95--1.52)   0.125       1,966              1.6 (1,454)
  35 to 44 y                     1.06 (0.83--1.35)   0.666       1,905              1.2 (1,457)
  45 y and over                  1.07 (0.84--1.35)   0.594       1,918              0.3 (1,446)
  **Sex and age: males**                                                            
  15 to 24 y                     1.40 (1.13--1.73)   0.002       2,169              6.6 (1,540)
  25 to 34 y                     1.16 (0.90--1.49)   0.265       1,629              3.6 (1,173)
  35 to 44 y                     1.11 (0.85--1.46)   0.428       1,538              2.8 (1,133)
  45 y and over                  0.97 (0.75--1.25)   0.792       1,566              0.8 (1,174)
  **Sex and age: females**                                                          
  15 to 24 y                     1.75 (1.08--2.84)   0.023       629                1.2 (541)
  25 to 34 y                     1.67 (0.88--3.18)   0.119       337                0.5 (281)
  35 to 44 y                     0.76 (0.42--1.41)   0.388       367                0.4 (324)
  45 y and over                  1.80 (0.97--3.32)   0.062       352                0.1 (272)
  **Cumulative SSRI exposure**                                                      
  Low SSRI exposure              1.27 (1.10--1.47)   0.001       896                n/a
  Moderate SSRI exposure         1.11 (0.96--1.28)   0.163       1,038              n/a
  High SSRI exposure             1.06 (0.88--1.29)   0.528       562                n/a
  **Type of SSRI medication**                                                       
  Fluoxetine                     1.16 (0.88--1.52)   0.287       1,276              1.4 (916)
  Citalopram                     1.14 (0.96--1.36)   0.130       3,088              0.6 (2,292)
  Paroxetine                     1.24 (0.87--1.77)   0.227       784                1.2 (577)
  Sertraline                     1.22 (1.02--1.46)   0.031       3,003              1.0 (2,241)
  Escitalopram                   1.02 (0.77--1.34)   0.904       1,446              1.2 (1,051)

Analyses excluded individuals with only one dispensed prescription. There were too few individuals for separate analyses of fluvoxamine.

n/a, not applicable.

Sensitivity Analyses {#sec021}
--------------------

In sensitivity analyses, our results showed some differences for individual SSRIs; there was a significantly higher hazard for violent crime conviction in individuals prescribed sertraline ([Table 3](#pmed.1001875.t003){ref-type="table"}) and for violent crime conviction in individuals prescribed citalopram and sertraline after eliminating periods of concurrent use of two different SSRIs, thus adjusting for switching effects between SSRIs ([Table 4](#pmed.1001875.t004){ref-type="table"}). For violent crime arrests, the increased association with citalopram remains ([Table 4](#pmed.1001875.t004){ref-type="table"}).

10.1371/journal.pmed.1001875.t004

###### Sensitivity analyses: rates of different adverse outcomes in individuals treated with SSRI medication and other antidepressants compared to non-treatment periods in the same person using stratified Cox regression models.

![](pmed.1001875.t004){#pmed.1001875.t004g}

  Outcome/Exposure                                                                                                                        HR (95% CI)         *p*-Value   Number of Events
  --------------------------------------------------------------------------------------------------------------------------------------- ------------------- ----------- ------------------
  **Alternative outcomes**                                                                                                                                                
  Convicted of a non-violent crime                                                                                                        1.10 (1.05--1.15)   \<0.001     51,888
  Convicted of a substance-related crime                                                                                                  0.99 (0.93--1.06)   0.825       17,922
  Arrested for a violent crime                                                                                                            1.13 (1.08--1.18)   \<0.001     33,556
  Arrested for a non-violent crime                                                                                                        1.05 (1.02--1.08)   \<0.001     85,645
  Arrested for a substance-related crime                                                                                                  0.99 (0.94--1.05)   0.772       23,919
  Non-fatal injury from an accident                                                                                                       1.20 (1.18--1.23)   \<0.001     241,900
  Emergency treatment for alcohol intoxication or misuse                                                                                  1.06 (1.03--1.09)   \<0.001     70,262
  Psychiatric hospitalisation[^ǂ^](#t004fn002){ref-type="table-fn"}                                                                       0.96 (0.93--0.99)   0.012       200,999
  **Type of SSRI medication, with violent crime convictions as outcome, excluding periods of concurrent use of other SSRI medications**                                   
  Fluoxetine                                                                                                                              1.25 (0.95--1.65)   0.115       1,276
  Citalopram                                                                                                                              1.20 (1.00--1.43)   0.048       3,088
  Paroxetine                                                                                                                              1.23 (0.87--1.75)   0.250       784
  Sertraline                                                                                                                              1.22 (1.01--1.46)   0.037       3,003
  Escitalopram                                                                                                                            1.07 (0.81--1.44)   0.613       1,446
  **Type of SSRI medication, with violent crime convictions as outcome, adjusted for other SSRI medications**                                                             
  Fluoxetine                                                                                                                              1.17 (0.89--1.53)   0.255       1,276
  Citalopram                                                                                                                              1.16 (0.97--1.37)   0.102       3,088
  Paroxetine                                                                                                                              1.26 (0.89--1.79)   0.194       784
  Sertraline                                                                                                                              1.23 (1.03--1.48)   0.023       3,003
  Escitalopram                                                                                                                            1.07 (0.82--1.42)   0.604       1,446
  **Type of SSRI medication, with violent crime arrests as outcome**                                                                                                      
  Fluoxetine                                                                                                                              1.03 (0.91--1.17)   0.612       4,836
  Citalopram                                                                                                                              1.15 (1.06--1.24)   0.001       12,595
  Paroxetine                                                                                                                              1.24 (1.06--1.24)   0.007       2,840
  Sertraline                                                                                                                              1.08 (0.99--1.17)   0.057       11,976
  Escitalopram                                                                                                                            1.06 (0.93--1.20)   0.383       5,097
  **Other antidepressants and medications, with violent crime convictions as outcome**                                                                                    
  Venlafaxine                                                                                                                             1.39 (1.10--1.78)   0.007       1,843
  Duloxetine                                                                                                                              1.26 (0.88--1.81)   0.200       761
  Tricyclics                                                                                                                              1.05 (0.71--1.55)   0.821       804
  Heterocyclics                                                                                                                           1.64 (0.92--2.95)   0.097       330
  Mirtazapine                                                                                                                             0.71 (0.59--0.88)   0.001       3,258
  Moclobemide                                                                                                                             1.70 (0.36--7.91)   0.502       46
  Bupropion                                                                                                                               0.42 (0.14--1.24)   0.118       211
  Diuretics                                                                                                                               0.80 (0.67--0.95)   0.012       3,450

Analyses excluded individuals with only one dispensed prescription. There were too few individuals for separate analyses of fluvoxamine.

^**ǂ**^Adjusted model: please see [S1 Methods](#pmed.1001875.s002){ref-type="supplementary-material"} for more details.

In further analyses, the relationship between SSRI treatment and other outcomes was examined ([Table 4](#pmed.1001875.t004){ref-type="table"}), and the results showed an increased risk of violent crime arrests, non-violent crime convictions, and non-violent crime arrests with SSRI treatment. Furthermore, an increased risk of non-fatal injuries from accidents was found (HR = 1.20, 95% CI 1.18--1.23, *p \<* 0.001). The possible role of alcohol misuse as a time-varying confounder was tested by using emergency inpatient and or outpatient treatment for alcohol intoxication or misuse as an outcome, showing an increased risk during times of medication (HR = 1.06, 95% CI 1.03--1.09, *p \<* 0.001). The risk of hospitalisation for psychiatric care was also examined, showing a slightly decreased risk with SSRI treatment (HR = 0.96, 95% CI 0.93--0.99, *p =* 0.012). When we investigated other antidepressant classes, we found a significant association between medication use and violent crime conviction for individuals prescribed venlafaxine. The risk of being convicted of a violent crime was reduced when on mirtazapine. Finally, an inverse association between violent crime conviction and diuretics was found using the within-individual model (HR = 0.80, 95% CI 0.67--0.95, *p =* 0.012).

When all analyses were stratified by age ([S1 Table](#pmed.1001875.s003){ref-type="supplementary-material"}), the increased risk of being convicted of a violent crime remained in individuals aged 15 to 24 y after adjustment for concurrent psychotropic medications (HR = 1.45, 95% CI 1.21--1.74, *p \<* 0.001). Results also showed that low SSRI exposure was associated with an increased risk of being convicted of a violent crime in this age band only (HR = 1.62, 95% CI 1.23--2.13, *p \<* 0.002). Furthermore, significant associations were shown for violent crime arrests and non-violent crime arrests and convictions for individuals aged 15 to 24 y, and also for individuals aged 25 to 34 y, although associations were weaker in the latter age band. The increased risk of non-fatal injuries from accidents remained significant for all ages. Results also showed that individuals aged 15--24, 25--34, and 35--44 y had an increased risk of emergency inpatient or outpatient treatment for alcohol intoxication or misuse (HR = 1.98, 95% CI 1.76--2.21, *p \<* 0.001; HR = 1.33, 95% CI 1.21--1.46, *p \<* 0.001; HR = 1.08, 95% CI 1.01--1.14, *p =* 0.015, respectively). However, individuals aged 45 y and older showed a slightly decreased risk of emergency inpatient or outpatient treatment for alcohol intoxication or misuse (HR = 0.96, 95% CI 0.93--0.99, *p =* 0.028).

To test whether individuals who had been dispensed only one prescription differed from the rest of the cohort, we also carried out a within-individual analysis including these individuals only. No significant association of SSRI treatment with violent crime conviction was found for this group (HR = 0.73, 95% CI 0.45--1.17, *p =* 0.193). To account for the possibility of reverse causation, i.e., that individuals are more likely to take SSRIs after committing a crime, we excluded 996 individuals who received SSRIs within 60 d of committing a violent crime, and the risk increase remained ([S2 Table](#pmed.1001875.s004){ref-type="supplementary-material"}). We then excluded 608 individuals who received SSRIs within 30 d of committing of a violent crime, and the risk increase remained similar ([S2 Table](#pmed.1001875.s004){ref-type="supplementary-material"}). When we excluded those who received medication within 14 d (356 individuals) or 7 d (197 individuals) of committing a violent crime, similar risk increases were found ([S2 Table](#pmed.1001875.s004){ref-type="supplementary-material"}). No material differences were found when we repeated this analysis with violent crime arrests as an outcome ([S2 Table](#pmed.1001875.s004){ref-type="supplementary-material"}). When we carried out a conditional Poisson regression, a similar pattern of findings was found (incidence rate ratio for violent crime conviction = 1.18, 95% CI 1.09--1.27, *p =* 0.001). When treatment periods were defined as no breaks in prescription coverage of more than 3 or 4 mo, instead of 6 mo, no material differences were found in the within-individual models ([S2 Table](#pmed.1001875.s004){ref-type="supplementary-material"}). When we tested for delayed treatment effects, no material differences were found for the association between SSRI treatment and violent crime convictions when the treatment period was considered to start 8 wk after the SSRI prescription was dispensed (HR = 1.21, 95% CI 1.02--1.43, *p =* 0.031). Similar effects were found when testing for SSRI discontinuation effects up to 3 wk or 12 weeks, respectively, after the last dispensed prescription ([S2 Table](#pmed.1001875.s004){ref-type="supplementary-material"}).

Discussion {#sec022}
==========

In this study, we examined the possible association between SSRIs and violent crime using a large population-based cohort that included 856,493 individuals prescribed SSRIs. There were three main findings. First, using a within-individual design, there was an association between SSRI prescriptions and violent crime convictions. With age stratification, there was an increased hazard of violent crime convictions in individuals aged 15 to 24 y, and no significant association in older individuals. A second finding was that the association in individuals aged 15--24 y was consistent when looking at a related antidepressant (venlafaxine, a serotonin--norepinephrine reuptake inhibitor), considering four other outcomes (violent crime arrests, non-violent crime convictions and arrests, and non-fatal accidental injuries), or using another design (conditional Poisson regression). Third, the association of SSRI treatment with violent crime was not found for moderate or high SSRI use, including in those aged 15--24 y.

The finding of a modest risk association in younger people is consistent with trial data showing that children and adolescents respond differently than adults to SSRIs \[[@pmed.1001875.ref034]\], and with reported increases in suicide-related outcomes in adolescents prescribed SSRI medication in both observational studies and clinical trials \[[@pmed.1001875.ref011],[@pmed.1001875.ref032],[@pmed.1001875.ref035]\], although this finding is not supported by meta-analyses of trial data \[[@pmed.1001875.ref036],[@pmed.1001875.ref037]\]. These associations may be moderated by impulsivity and risk-taking, which could explain the similar association we report with accidents, and the weaker associations with non-violent crime convictions and arrests. A recent observational investigation also found increases in suicidal behaviour in a large US cohort aged less than 25 y \[[@pmed.1001875.ref038]\]. The US investigation found that younger people receiving the modal antidepressant dose were at increased risk of deliberate self-harm compared to adults, and this risk was further increased in individuals receiving higher doses. The apparent contrast with our findings on medication dose may be because the US study looked at risks in those initiating treatment, while our study examined all treatment periods. Importantly, this US study saw no increased hazard of self-harm in those over 25 y, analogous to our null finding for crime outcomes for those over 25 y. The reasons for the age-dependent differences are still poorly understood, but the adolescent brain may be particularly sensitive to pharmacological interference, as has been demonstrated in animal studies \[[@pmed.1001875.ref038]--[@pmed.1001875.ref043]\]. Yet, the possible adverse effects associated with SSRI use appear to be separate from its therapeutic ones; treatment effects have been demonstrated \[[@pmed.1001875.ref010],[@pmed.1001875.ref037]\], particularly for fluoxetine and escitalopram, which are approved by the US Food and Drug Administration for treating adolescent depression \[[@pmed.1001875.ref034]\].

The reported association between SSRIs and violent crime in young people cannot be interpreted causally because of confounding by indication. This confounding was confirmed in our study by the difference between the hazards reported in between-individual and within-individual analyses. Hence we focused on the within-individual analyses: crime outcomes in the same individuals when they were taking SSRIs compared to when they were not taking SSRIs, thus adjusting for all factors that were constant within the individual. However, this approach cannot fully account for time-varying risk factors, such as increased drug or alcohol use during periods of SSRI medication, worsening of symptoms, or a general psychosocial decline. We attempted to address the first of these by investigating substance-related convictions, one proxy for problem substance use, and recorded rates of emergency treatment for alcohol-related problems. Although we did not find an association of SSRI treatment with substance-related convictions, this was a crude outcome with an incidence of 1.7%. An alternative marker of alcohol use was the rate of emergency inpatient or outpatient treatment for alcohol intoxication or misuse, where we found some support for an increasing rate during SSRI medication, which is in keeping with one case series \[[@pmed.1001875.ref044]\]. Although emergency treatment for alcohol intoxication or misuse is a more sensitive measure than alcohol-related crimes, it needs further clarification using prospective clinical designs. Symptom severity may moderate the association between SSRIs and the adverse outcomes reported in this study, and younger people on SSRIs may be less adherent than others, and may have more residual symptoms, such as impulsivity and hostility, which are risk factors for violence \[[@pmed.1001875.ref045]\]. This is underscored by recent epidemiological work that suggested that depression and bipolar disorder are independent risk factors for violent crime \[[@pmed.1001875.ref046],[@pmed.1001875.ref047]\]. If these underlying conditions are partially treated---especially in bipolar patients who are not also prescribed a mood stabiliser \[[@pmed.1001875.ref027]\]---then residual symptoms may partly explain any association. This is further suggested by our finding that the increased hazard for violent crime conviction in younger people was not found in individuals with therapeutic SSRI exposures (≥1 DDD/day). However, the finding that there was a risk increase for non-violent crime arrests and non-violent crime convictions with SSRI use suggests a non-specificity in our findings that could be explained by time-varying confounders, or that the links may be mediated by factors that increase the risk of both violent and non-violent crime. The risk increases for non-violent crime outcomes were smaller than those for violent crime outcomes, which suggests some complexity to the possible mechanisms involved. A final possibility is that non-specific treatment factors, such as contact with health care staff, may partly explain the relationship. As most of the individuals in the sample were outpatients, and unlikely to see health care staff regularly once treatment was initiated, these factors may not be strong. In addition, the finding that violent crime conviction was inversely associated with a group of non-psychotropic medications (diuretics) suggests that, if anything, non-specific treatment effects would reduce any observed association.

Another possible challenge to the results is reverse causality---that the observed association was due to individuals taking SSRIs after being arrested for a crime (for various reasons, including coping with the anxiety and stress of arrest or that taking SSRIs might mitigate their criminal sanction). In order to address reverse causality, we excluded all persons who received SSRIs within 7, 14, 30, or 60 d after committing a violent crime, and the association between SSRI treatment and violent crime convictions remained significant, with no material change in risk. Differences between individual SSRIs were examined. The increased association between paroxetine and citalopram use and violent crime arrests could be due to their poorer efficacy and/or shorter half-life compared with other SSRIs \[[@pmed.1001875.ref034],[@pmed.1001875.ref048]\]. Shorter half-lives are linked with withdrawal effects on discontinuation, with increased agitation and possible hostility \[[@pmed.1001875.ref034],[@pmed.1001875.ref049]\]. Further, the single-dose and mean steady-state half-life of SSRIs with short half-lives are shorter in adolescents than in adults, and aggression thus could be a withdrawal rather than side effect \[[@pmed.1001875.ref034]\]. In support of this, venlafaxine and, non-significantly, the heterocyclics were also linked with higher risks of violent crime convictions than SSRIs, and these medications have shorter half-lives and poorer efficacy \[[@pmed.1001875.ref034],[@pmed.1001875.ref048]\]. Moreover, we found an increased risk of violent crime conviction for low SSRI exposure only, which is consistent with the reported links with antidepressants with shorter half-lives and case reports of increased hostility and aggression in children and adolescents at low starting doses in the first weeks of SSRI treatment \[[@pmed.1001875.ref050],[@pmed.1001875.ref051]\]. Escitalopram, with a half-life similar to that of citalopram, was also associated with increased violent crime convictions in younger persons ([S1 Table](#pmed.1001875.s003){ref-type="supplementary-material"}). However, any increased risks of post-cessation withdrawal for violent crime would not be included as related to SSRIs using the design in the current study if the medication was discontinued as planned, and therefore our estimates may be conservative. Our sensitivity analyses to measure post-cessation withdrawal (considering the treatment period to continue up to 3 wk or 12 wk after the date the last SSRI prescription was dispensed) nevertheless showed no material difference in the increased risk of violent crime conviction. An alternative explanation could be that the increased risk of some SSRIs is confounded by psychiatric morbidity; citalopram, escitalopram, and paroxetine are not recommended as first-line treatment for children and adolescents by the Swedish National Board of Health and Welfare, and thus are reserved for treatment-resistant patients with more severe problems \[[@pmed.1001875.ref052]\]. Further work will need to validate differences between SSRIs and dosing strategies, and investigate underlying mechanisms in younger populations. One potentially important explanatory factor will be the timing of doses, which requires further examination.

There are two principal clinical implications arising from this study. First, no association between SSRIs and violent crime convictions was found for the majority of people who were prescribed these medications, including individuals aged 25 y and older. Second, the risk increase we report in young people is not insignificant, and hence warrants further examination. If our findings related to young people are validated in other designs, samples, and settings, warnings about an increased risk of violent behaviours while being treated with SSRIs may be needed. Any such changes to the advice given to young persons prescribed SSRIs will need to be carefully considered, as the public health benefit from decreases in violence following restrictions in SSRI use may be countered by increases in other adverse outcomes (such as more disability, rehospitalisation, or suicides) \[[@pmed.1001875.ref053]\]. From a public health perspective, this worsening of overall morbidity and mortality might argue against restrictions on the primary care prescribing of SSRIs as long as potential risks are disclosed \[[@pmed.1001875.ref054]\].

The present study was characterised by several strengths. The study included a large population-based cohort with longitudinal data retrieved from national registers. Information on SSRIs was complete, as each prescription that is dispensed is registered in the Swedish Prescribed Drug Register. Using a within-individual design allowed us to adjust for many unobserved factors that may bias estimates. Although a marginal structural model would have been desirable because of its ability to handle time-varying confounding factors that are also predicted by treatment history, such a model could be used only in a between-individual design that includes measures of all confounding factors. Since many confounders are most likely unobserved, we used a within-individual design as our principal approach. This allowed us to adjust for both measured and unmeasured time-invariant confounding factors, as well as for some measured time-varying confounders that are not predicted by exposure history (like sex and age). Limitations of the study include the use of diagnoses from the national patient register, which only includes diagnoses from specialists. Also, the use of official sources of data for crime outcomes is likely to underestimate true rates of crime and possibly involve selection effects. However, we tried to address such biases by using arrests with preliminary investigations in addition to convictions and also by examining accidents. It is not clear whether these findings will translate to less severe forms of violence or those not reported to the police, and triangulating the findings with information on self- or informant-reported violence will be an important future research direction. Another limitation is that detailed information about the actual prescriptions was not available. Although our data are an improvement over prescription data---as they reflect prescriptions that are dispensed by pharmacies to individuals---we were unable to account for lack of, or variations in, adherence. This problem is parallel to non-adherence in randomised controlled trials, and our within-individual estimate is comparable to the intention-to-treat analysis used in randomised controlled trials. If individuals consumed SSRIs during periods when we assumed that they were not, then this should reduce the hazards reported and would suggest that our estimates are underestimates. A possible source of underestimation is that we excluded persons who were prescribed SSRIs on only one occasion, who may have discontinued the medications due to adverse effects that were not included. We thus carried out analyses where individuals with a single prescription were included, and found no material differences in hazard of violent crime conviction. Another possible source of underestimation is that we used a conservative approach to measure the end of a treatment period (we defined this as the date the last SSRI prescription in a treatment period was dispensed), which could result in slightly lower sensitivity (i.e., individuals classified as unmedicated when truly medicated). However, sensitivity analyses using less conservative approaches to measure the end of a treatment period (3 wk and 12 wk after the last dispensed SSRI prescription in a treatment period) resulted in a similarly increased risk of violent crime conviction. Sweden has prescription rates of SSRIs that are higher than the average for Europe (5-y mean DDD/1,000 individuals/day: Sweden = 70.1; across 29 European countries = 40.0) \[[@pmed.1001875.ref014]\] and similar to the US (10.8% treated in our cohort between 2006--2009 compared to 10.1% treated in the US in 2005) \[[@pmed.1001875.ref055]\]. In relation to criminality, Sweden has similar police-reported assault rates as the US \[[@pmed.1001875.ref056]\]. Finally, there might be residual confounding for the within-individual estimates due to unmeasured time-varying confounders. However, we are not aware of any statistical method that also allows adjustment for unmeasured time-varying confounders.

In summary, we demonstrated associations between SSRIs and violent crime that vary by age group. The clinical and public health implications of this require careful consideration, and validation in other settings.
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